

**Review Article** 

# Systematic review and meta-analysis comparing ventilatory support in chemical, biological and radiological emergencies\*

Israel Baptista de Souza Borges<sup>1</sup>

Magali Rezende de Carvalho<sup>2</sup>

Marcel de Souza Quintana<sup>3</sup> https://orcid.org/0000-0001-5186-9791 Alexandre Barbosa de Oliveira<sup>1</sup>

b https://orcid.org/0000-0003-4611-1200

- \* Paper extracted from master`s thesis "Efetividade de técnicas de suporte ventilatório em cenários simulados de emergências e desastres químicos, biológicos, radiológicos e nucleares: metanálise", presented to Universidade Federal do Rio de Janeiro, Escola de Enfermagem Anna Nery, Rio de Janeiro, RJ, Brazil.
- <sup>1</sup> Universidade Federal do Rio de Janeiro, Escola de Enfermagem Anna Nery, Rio de Janeiro, RJ, Brazil.
- <sup>2</sup> Universidade Federal Fluminense, Escola de Enfermagem Aurora Afonso Costa, Niterói, RJ, Brazil.
- <sup>3</sup> Fundação Oswaldo Cruz, Instituto Nacional de Infectologia, Rio de Janeiro, RJ, Brazil.

Objective: to compare the mean development time of the techniques of direct laryngoscopy and insertion of supraglottic devices; and to evaluate the success rate in the first attempt of these techniques, considering health professionals wearing specific personal protective equipment (waterproof overalls; gloves; boots; eye protection; mask). Method: meta-analysis with studies from LILACS, MEDLINE, CINAHL, Cochrane, Scopus and Web of Science. The keywords were the following: *personal protective equipment*; *airway* management; intubation; laryngeal masks. Results: in the "reduction of the time of the procedures" outcome, the general analysis of the supraglottic devices in comparison with the orotracheal tube initially presented high heterogeneity of the data (I<sup>2</sup> = 97%). Subgroup analysis had an impact on reducing heterogeneity among the data. The "laryngeal mask as a guide for orotracheal intubation" subgroup showed moderate heterogeneity ( $I^2 = 74\%$ ). The "2<sup>nd</sup> generation supraglottic devices" subgroup showed homogeneity ( $I^2 = 0\%$ ). All the meta-analyses favored supraglottic devices. In the "success in the first attempt" outcome, moderate homogeneity was found ( $I^2 = 52\%$ ), showing a higher proportion of correct answers for supraglottic devices. Conclusion: in the context of chemical, biological or radiological disaster, the insertion of the supraglottic device proved to be faster and more likely to be successful by health professionals. PROSPERO record (CRD42019136139).

Descriptors: Airway Management; Personal Protective Equipment; Intubation; Laryngeal Masks; Meta-Analysis; Disasters.

## How to cite this article

Borges IBS, Carvalho MR, Quintana MS, Oliveira AB. Systematic review and meta-analysis comparing ventilatory support in chemical, biological and radiological emergencies. Rev. Latino-Am. Enfermagem. 2020;28:e3347. [Access 1 1]; Available in: \_\_\_\_\_\_\_. DOI: http://dx.doi.org/10.1590/1518-8345.4024.3347. URL

# Introduction

Several emergency situations are triggered by the malicious or accidental use of chemical, biological or radiological agents, which can result in respiratory failure for the victims. The terrorist attacks in Syria with the Sarin neurotoxic gas in 2013 and 2017 can be cited<sup>(1)</sup>. In Brazil, in 2013, in the city of Santa Maria – Rio Grande do Sul, there was an accidental fire in a nightclub, which generated the emission of hydrogen cyanide, a chemical agent that, at that time, was responsible for the increase in clinical cases of acute respiratory failure, which resulted in the drastic death of 242 people and respiratory distress in approximately 1,000 victims<sup>(2)</sup>.

As for the biological agents, in West Africa, the Ebola virus epidemic in 2014 triggered an international civicmilitary response that left several countries on alert. The epidemic claimed the lives of thousands<sup>(3-4)</sup>. In 2015, in Brazil, the first suspected case of Ebola was reported, which mobilized the health sector and provided the opportunity for the preparation of health professionals in relation to the specific protective equipment they should wear, as well as transportation and adequate health care addressed to the person with the suspected condition. This initiative was justified by the pathophysiology of the disease itself, which stimulates an inflammatory response, followed by an immuno-suppressive phase, causing respiratory failure due to blood aspiration and septic shock<sup>(5-6)</sup>.

In relation to the inadvertent use of radiological agents, in 1987, in Goiânia, a municipality belonging to the state of Goiás (Brazil), a relevant radiological accident with cesium-137 had worldwide repercussion from the rupture of a lead capsule of an abandoned radiotherapy device in a disabled clinic. The consequence was the monitoring of 112,000 citizens, health care for 249 irradiated or contaminated people and four deaths, in addition to the marks it left as the worst radiological disaster in the world that occurred outside nuclear plants<sup>(7)</sup>.

Faced with such situations, when considering that first aids often occur with the victim still contaminated by a chemical, biological or radiological agent, it is recommended that at least the health professional use level C personal protective equipment, which essentially consists of waterproof overalls, gloves, boots, eye protection, and mask<sup>(3,8-10)</sup>.

In view of the dimension and severity that events of this nature can cause, it is necessary to provide adequate protection to the health professionals, especially to the nursing team, who must be able to fully exercise their craft to alleviate suffering and care for the people affected in a safe and fruitful way. Indeed, the procedures analyzed and the individual protection equipment indicated to the health professionals in these complex circumstances confirm the need to discuss better standards of response and risk management, as well as the importance of having effective health technologies in calamitous scenarios<sup>(11)</sup>.

Additionally, it is worth mentioning the authorization issued by the Federal Nursing Council (Brazil), through its Opinion No. 1/2015, for trained nurses to proceed with the insertion of supraglottic devices, in case of urgencies and emergencies. In this sense, in a scenario of emergencies and disasters involving chemical, biological or radiological agents, the autonomy of these professionals is reasserted in the management of the airways in assisting victims with respiratory failure<sup>(12)</sup>.

In face of the agents that cause respiratory failure, there are procedures, such as direct laryngoscopy and the insertion of supraglottic devices, for establishing a patent airway and, consequently, a reduced risk of death<sup>(13-14)</sup>.

However, there are divergences among studies on the "reduction of time to perform the procedure" and "success in the first attempt of each applied technique" outcomes. As an example, there is a study that recommends direct laryngoscopy<sup>(15)</sup>, as well as a study recommending supraglottic devices<sup>(16)</sup>, both published in 2018. For this reason, a meta-analysis was deemed necessary, since these outcomes are crucial as they directly impact the survival of victims of respiratory failure in a calamitous scenario, and provide substantial subsidies in the decision-making of the health professional about which technology should be used as a priority.

Therefore, the objectives of this study are to compare the mean of development time of the techniques of direct laryngoscopy and insertion of supraglottic devices; and to evaluate the success rate in the first attempt of these techniques, considering health professionals wearing specific personal protective equipment (waterproof overalls; gloves; boots; eye protection; mask).

#### Method

This systematic review and meta-analysis, under PROSPERO (International Prospective Register of Ongoing Systematic Reviews) record CRD42019136139, followed the guidelines recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The MEDLINE (1946-2019), Cochrane (1999-2019), Scopus (1966-2019), Web of Science (1900-2019), LILACS (1987-2019), and CINAHL (1961-2019) databases were used, in addition to a manual search in the reference list of the selected studies, a search in the list of studies related to each eligible study on the PubMed platform, and a search in Google Scholar. The inclusion criteria adopted were the following: randomized clinical trial with comparison

between orotracheal intubation and insertion of supraglottic devices performed by health professionals using level C personal protective equipment. The exclusion criteria were the following: randomized clinical trial with comparison between orotracheal intubation and insertion of supraglottic devices performed by health professionals using level C personal protective equipment on children or pediatric-sized mannequins; and studies that did not provide the necessary data for the meta-analysis, such as number of participants, mean time and standard deviation. The study collection period was between March 8<sup>th</sup> and August 30<sup>th</sup>, 2019; and there were no restrictions as for language or year of publication.

The search strategies were configured as follows:

In MEDLINE: ((((((respiratory insufficiency[MeSH Terms]) OR manikins[MeSH Terms]) OR nerve agents[MeSH Terms]) OR chemical warfare agents[MeSH Terms]) OR hazardous substances[MeSH Terms])) AND (((((airway management[MeSH Terms]) OR intubation, Intratracheal[MeSH Terms]) OR Personal Protective Equipment[MeSH Terms]) OR protective clothing[MeSH Terms]) OR laryngoscopy[MeSH Terms])) AND laryngeal masks[MeSH Terms].

In Scopus: (TITLE-ABS-KEY (airway AND management) OR TITLE-ABS-KEY (manikin\*) AND TITLE-ABS-KEY (personal AND protective AND equipment) OR TITLE-ABS-KEY (cbrn) OR TITLE-ABS-KEY (cbrn AND ppe) OR TITLE-ABS-KEY ( chemical AND suit) OR TITLE-ABS-KEY (protective AND clothing) AND TITLE-ABS-KEY (intubation)).

Τn Cochrane: (airway\*): ti,ab,kw AND (intubation\*):ti,ab,kw AND ("personal protective equipment"\*):ti,ab,kwOR(protectiveclothing\*):ti,ab,kw AND (laryngeal mask\*):ti,ab,kw. Below is the strategy in Web of Science: ALL FIELDS: (airway management) AND TITLE: (manikin\*) OR TITLE: (cadaver\*) AND TITLE: (personal protective equipment) OR TITLE: (CBRN-PPE) AND ALL FIELDS: (intubation) AND ALL FIELDS: (laryngeal mask\*) OR ALL FIELDS: (supraglottic). Refined by: WEB OF SCIENCE CATEGORIES: (EMERGENCY MEDICINE).

The studies derived from the application of the strategies were selected by two independent reviewers and filtered by reading their titles and abstracts, with due registration on the studies' eligibility form. After checking the lists, a Kappa coefficient of 0.74 was obtained, a satisfactory value that reflected the objectivity and clarity of the data to be collected<sup>(17)</sup>. Disagreements regarding the inclusion of studies were resolved in a consensus meeting. Subsequently, citations were exported to the EndNote online reference manager. All the studies from this first selection were analyzed in their full texts.

The data collected from each study were organized in a data extraction instrument containing the following: authors' names; title; country of origin; year and magazine of publication; study population and environment; types of ventilatory support devices; number of participants; mean time spent performing the technique; standard deviation; and success rate in the first attempt of each procedure.

According to the Cochrane collaboration tool, for assessing the risk of bias in randomized studies, each eligible study was classified as low, moderate, or high risk of bias<sup>(18)</sup>.

The meta-analysis was developed using the RevMan 5.3 software, whose data were worked under random effect, with calculation of the difference in time means for the first objective, and the difference of proportion/risk for the second objective. When the study did not present all the data for meta-analysis, but offered a means for calculating it, the data was calculated. The I test was considered low heterogeneity with  $I^2 < 50\%$ ; moderate heterogeneity with  $I^2$  test between 50 and 75%; and high heterogeneity with  $I^2$  test > 75%<sup>(19)</sup>. Additionally, the analysis was treated by subgroups when  $I^2 > 50\%$ . The significance level was set at 0.05. The GRADE system was used to assess the quality of the evidence, classified as high, moderate, low, and very low, as well as the strength of the recommendation, classified as strong or weak<sup>(20)</sup>.

### Results

Figure 1 shows the product of the search strategies used.

In the sequence, Figure 2 represents the characterization of the 10 included studies, where all are prospective and of the crossover type; that is, the participants experienced the application of techniques with the supraglottic device and the orotracheal tube.

In the selected studies, a comparison between 1<sup>st</sup> and 2<sup>nd</sup> generation supraglottic devices was identified, comprising models of laryngeal mask and laryngeal tube. This classification is based on the chronological evolution and improvement of intrinsic characteristics of the supraglottic devices such as the angle of curvature for better accommodation in the larynx; the sealing ability in the larynx to withstand pressure ventilation; a composition that is difficult to deform in case of bites by the victim; and the creation of a gastric drainage route<sup>(13)</sup>.

It should be noted that there were studies that compared more than one supraglottic device with the orotracheal tube, which made meta-analyses and their recommendations more robust.




Figure 1 - Flowchart of the Systematic Review in PRISMA format

Authors (Year)	Assessed technology	Participants (n)	Number of attempts	Technique application instrument
Ben-Abraham; Weinbroum (2004) <sup>(21)</sup>	1 <sup>st</sup> generation laryngeal mask; Orotracheal tube	Non-anesthetist health professional (10); Anesthetist (10)	2	Adult size Laerdal Airway Management Trainer mannequin
Castle, et al. (2009) <sup>(22)</sup>	1 <sup>st</sup> generation laryngeal mask; Orotracheal tube	Prehospital physician (4); Resuscitation officer (6); Paramedic (14), Anesthetist (15); Emergency physician (25).	2	Adult size Laerdal Airway Management Trainer mannequin
Castle, et al. (2010) <sup>(23)</sup>	1 <sup>st</sup> generation laryngeal mask; Orotracheal tube	Pre-hospital care physician; Resuscitation officer; Paramedic; Senior and junior anesthetist; Senior and junior emergency physician (75).	2	Adult size Laerdal Airway Management Trainer mannequin
Flaishon, et al. (2004) <sup>(24)</sup>	1 <sup>st</sup> generation laryngeal mask; Orotracheal tube	Anesthetist (15)	1	Human being
Garner; Laurence; Lee (2004) <sup>(10)</sup>	1 <sup>st</sup> generation laryngeal mask; Orotracheal tube	Paramedic (3); Emergency physician (3); Anesthetist (2)	1	Adult mannequin
Greenland, et al. (2007) <sup>(25)</sup>	ILMA* laryngeal mask; Orotracheal tube	Senior and Junior Anesthetist (18)	1	Adult size Laerdal Airway Management Trainer mannequin
Ophir, et al. (2014) <sup>(26)</sup>	1 <sup>st</sup> generation laryngeal mask; 2 <sup>nd</sup> generation laryngeal mask; Laryngeal tube; Orotracheal tube	Anesthetist (20); Rescuer (26), Paramedic (27), General practitioner (24); Medical resident of different specialties (20)	3	Adult size Laerdal Airway Management Trainer mannequin
Plazikowski, et al. (2018) <sup>16</sup>	i-gel laryngeal mask; ILMA* laryngeal mask Orotracheal tube	Physician qualified as an anesthetist and emergency physician (30)	1	Adult size Laerdal Airway Management Trainer mannequin
Wang, et al. (2016) <sup>(27)</sup>	1 <sup>st</sup> generation laryngeal mask; Orotracheal tube	Senior and junior emergency physician (40)	1	Adult size Laerdal Airway Management Trainer mannequin
Weaver, et al. (2015) <sup>(28)</sup>	ILMA* laryngeal mask; Orotracheal tube	Junior Emergency Physician (37)	3	Adult size Laerdal Airway Management Trainer mannequin

\*ILMA = Laryngeal mask capable of guiding orotracheal intubation

Figure 2 - Characterization of the studies

It is worth mentioning that there were two studies whose lead author was an English nurse<sup>(22-23)</sup>, with 139 participants performing 278 times with the supraglottic device, and 258 times with the orotracheal tube. This represents 33.61% of the supraglottic device data and 31.97% of the orotracheal tube data for the meta-analyses. Such information reiterates the importance of this theme for nursing care practices in emergencies and disasters.

Using the Cochrane collaboration tool, the quality of each selected study was assessed. As shown in Figure 3, the following domains were evaluated: selection bias, performance bias, detection bias, attrition bias, and reporting bias<sup>(18)</sup>.

When considering that the final classification of the study should be based on the highest risk of bias found among the domains, selection bias stood out as the main criterion for attributing a moderate risk of bias. Three studies with a low risk of bias, six studies with a moderate risk of bias, and one study with a high risk of bias were identified. It was prioritized that the study reported how the random sequence and allocation secrecy were generated. Low risk of performance and detection bias was attributed to studies due to textual evidence in the sources of information and explanation of the extra author acquired via e-mail. Low risk was attributed in relation to attrition bias, as there was no provision of incomplete data. Regarding reporting bias, a low risk of bias was attributed, since no trace of attempted data manipulation was identified.





Figure 3 - Bias risk assessment of the studies

Study or subgroup     Mean     SD <sup>±+</sup> Total     Mean     SD <sup>±+</sup> Total     Weight IV <sup>4</sup> , random, 95% cl <sup>111</sup> Year     IV <sup>4</sup> , random, 95% cl <sup>111</sup> 1.1.1 I <sup>4</sup> Generation Devices     Ben-Abraham 2004 - LMA (A)§     39     11     15     54     24     15     4.8%     -15.00 [28.36, -164]     2004     +       Gamer 2004 - LMA (A)§     33     21.5     8     43.9     22.94     8     3.1%     -10.60 [23.23, 11.19]     2004       Castle 2009 - LMA 11     26.6     4.08     64     67.5     16.17     57     6.6%     -22.60 [27.27, -17.9]     2004     +       Castle 2009 - LMA 28     21.8     2.86     64     59.4     13.55     61     6.8%     -37.60 [45.26, -36.51 2009     +       Castle 2010 - LMA 12     2.77     17.7     34.7     11.4     117     6.9%     -7.35 [9.75, -4.95]     2016     +     -       Castle 2010 - LMA 25     21.5     61.9     75.50 [45.26, 47.7     14.4     117.6.9%     -7.35 [9.75, -4.95]     2016     +     -     -	Mean difference	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		
Flaishon 2004 - LMA (A)§ 39 11 15 54 24 15 4.8% -15.00 [-28.36, -1.64] 2004 Gamer 2004 - LMA (A)[1 38 0.8 10 26.4 7.5 10 6.6% -22.60 [-27.27, 71.93] 2004 + Castle 2009 - LMA 14 26.6 4.08 64 67.5 16.17 57 6.6% -40.90 [+6.22, -36.58] 2009 + Castle 2010 - LMA 2§ 21.8 2.86 64 59.4 13.55 61 6.6% -37.60 [+4.10, 7, 34.13] 2009 + Castle 2010 - LMA 2§ 21.5 6.19 75 59.1 25.54 72 6.4% -37.60 [+4.36, -31.54] 2010 Ophir 2014 - LMA† 18.9 7.57 117 34.7 11.4 117 6.9% -15.00 [+18.28, -13.22] 2014 + Wang 2015 - LMA† 10.51 4.39 40 17.86 6.38 40 6.9% -7.35 [+3.75, -4.95] 2015 Subtotal (95% CIIII) Heterogeneity: Tau <sup>2</sup> = 201.99; Ch <sup>2</sup> = 399.34; df = 9 (P < 0.00001); l <sup>2</sup> = 98% Summary effect test: Z = 5.79 (P < 0.00001) 11) 11.3 200 Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.67; df = 2 (P = 0.71); l <sup>2</sup> = 0% Subtotal (95% CIIII) Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.67; df = 2 (P = 0.71); l <sup>2</sup> = 0% Subtotal (95% CIIII) Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.67; df = 2 (P = 0.71); l <sup>2</sup> = 0% Subtotal (95% CIIII) Heterogeneity: Tau <sup>2</sup> = 13.27; Ch <sup>2</sup> = 7.82; df = 9 (P = 0.02); l <sup>2</sup> = 74%		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		
Ben-Abraham 2004 - LMA (A)   3.8 0.8 10 264 7.5 10 6.6% -22.60 [ $27.27, 17.93$ ] 2004 Castle 2009 - LMA 1‡ 26.6 4.08 64 67.5 16.17 57 6.6% -40.90 [ $45.22, -36.58$ ] 2009 Castle 2000 - LMA 2\$ 21.8 2.86 64 59.4 13.55 61 6.8% -37.60 [ $41.07, 34.13$ ] 2009 Castle 2010 - LMA 1‡ 25.7 8.4 75 70.3 32.82 68 6.0% -44.60 [ $52.63, -36.57$ ] 2010 Castle 2010 - LMA 1‡ 25.7 8.4 75 70.3 32.82 68 6.0% -44.60 [ $52.63, -36.57$ ] 2010 Castle 2010 - LMA 1\$ 10.51 4.39 40 17.86 6.38 40 6.9% -7.35 [ $9.75, -4.95$ ] 2015 Subtotal (95% CIIII) Heterogeneity: Tau <sup>2</sup> = 201.99; Chi <sup>2</sup> = 399.34; df = 9 ( $P < 0.00001$ ); $l2 = 98%$ Summary effect test: 2 = 5.79 ( $P < 0.00001$ ) 211 <b>1.1.2</b> 2 <sup>nd</sup> Generation Devices Ophir 2014 - LT† 19.5 5.22 117 34.7 11.4 117 6.9% -16.10 [ $18.30, -13.90$ ] 2014 Plazkowski 2018 - LMA - 20 <sup>++</sup> 18.6 4.13 117 34.7 11.4 117 6.9% -15.20 [ $17.47, 12.93$ ] 2014 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.67; df = 2 ( $P = 0.71$ ); $l2 = 0\%$ Summary effect test: 2 = 2.2.8 ( $P < 0.00001$ ) <b>1.1.3 Subgrupo ILMA</b> Greeniand 2007 - LLMA <sup>+</sup> 14 3.5 18 22.2 6.6 18 6.8% -8.20 [ $11.65, -4.75$ ] 2007 Weaver 2015 - LLMA <sup>+</sup> 10 3.11 30 24.36 7.01 30 6.8% -14.36 [ $17.10, -11.62$ ] 2018 <b>1.1.3 Subgrupo ILMA</b> Greeniand 2007 - LLMA <sup>+</sup> 14 3.5 18 22.2 6.6 18 6.8% -8.20 [ $11.65, -4.75$ ] 2007 Weaver 2015 - LLMA <sup>+</sup> 10 3.11 30 24.36 7.01 30 6.8% -14.36 [ $17.10, -11.62$ ] 2018 <b>1.1.3 Subgrupo ILMA</b> Greeniand 2007 - LLMA <sup>+</sup> 14 3.5 18 22.2 6.8 18 6.8% -8.20 [ $11.65, -4.75$ ] 2007 Weaver 2015 - LLMA <sup>+</sup> 10 3.11 30 24.36 7.01 30 6.8% -14.36 [ $17.10, -11.62$ ] 2018 <b>4</b> Subtotal (95% CIIII) Heterogeneity: Tau <sup>2</sup> = 13.27; Chi <sup>2</sup> = 7.82; df = 9 ( $P = 0.02$ ); $l2 = 7.4\%$		
Castle 2009 - LMA 14 26.6 4.08 64 67.5 16.17 57 6.6% -40.90 [ $45.22, -36.58$ ] 2009 - Castle 2010 - LMA 2§ 21.8 2.86 64 59.4 13.55 61 6.8% -37.60 [ $41.07, -34.13$ ] 2009 - Castle 2010 - LMA 2§ 21.5 6.19 75 59.1 25.54 72 6.4% -37.60 [ $43.66, -31.54$ ] 2010 - Castle 2010 - LMA 4§ 18.9 7.57 117 34.7 11.4 117 6.9% -15.80 [ $18.28, -13.22$ ] 2014 - Wang 2015 - LMA† 10.51 4.39 40 17.86 6.38 40 6.9% $-7.35$ [ $67.5, -4.95$ ] 2015 - LMA† 10.51 4.39 40 17.86 6.38 40 6.9% $-7.35$ [ $67.5, -4.95$ ] 2015 - LMA† 10.51 4.39 40 17.86 6.38 40 6.9% $-7.35$ [ $67.5, -4.95$ ] 2015 - LMA† 10.51 4.39 40 17.86 6.38 40 6.9% $-7.35$ [ $67.5, -4.95$ ] 2015 - LMA† 10.51 4.39 40 17.86 6.38 40 6.9% $-7.35$ [ $67.5, -4.95$ ] 2015 - LMA† 10.51 4.39 40 17.86 6.38 40 6.9% $-7.35$ [ $67.5, -4.95$ ] 2015 - LMA† 117 11.4 117 6.9% $-16.10$ [ $18.30, -13.90$ ] 2014 - Qphir 2014 - LMA - 2G** 18.6 4.13 117 34.7 11.4 117 6.9% $-16.10$ [ $18.30, -13.90$ ] 2014 - Qphir 2014 - LT† 19.5 5.22 117 34.7 11.4 117 6.9% $-16.10$ [ $18.30, -13.90$ ] 2014 - Plazikowski 2018 - LTA - 2G** 9.64 2.34 30 24.36 7.01 30 6.8% $-14.72$ [ $17.36, -12.08$ ] 2018 - LTA - 2G** 9.64 2.34 30 24.36 7.01 30 6.8% $-14.72$ [ $17.36, -12.08$ ] 2018 - LT + 19.5 0.67; df = 2 (P = 0.71); l <sup>2</sup> = 0% summary effect test: 2 = 2.2.8 (P < 0.00001)		
Castle 2009 - LMA $2\hat{S}$ 21.8 2.86 64 59.4 13.55 61 6.8% -37.60 [-41.07, -34.13] 2009 - Castle 2010 - LMA $1\frac{1}{4}$ 25.7 8.4 75 70.3 32.82 68 6.0% -44.60 [-52.63, -36.57] 2010 - Castle 2010 - LMA $2\hat{S}$ 21.5 6.19 75 591 25.54 72 6.4% -37.60 [-43.66, -31.54] 2010 - Ophir 2014 - LMA $\frac{1}{4}$ 18.9 7.57 117 34.7 11.4 117 6.9% -7.35 [-9.75, -4.95] 2014 - Wang 2015 - LMA $\frac{1}{4}$ 10.51 4.39 40 17.86 6.38 40 6.9% -7.35 [-9.75, -4.95] 2015 - Leterogeneity: Tau <sup>2</sup> = 201.99; Ch <sup>2</sup> = 39.34; df = 9 (P < 0.00001); l <sup>2</sup> = 98% Summary effect test: Z = 5.79 (P < 0.00001) 31) - 478 - 458 60.6% - 427.14 [-36.32, -17.96] - 458 60.6% - 42.64 20.6% - 15.20 [-17.47, -12.93] 2014 - 458 60.6% - 42.64 20.6% - 15.42 [-16.77, -14.06] - 458 60.6% - 42.61 [-43.6, -47.7] 2018 - 458 60.6% - 42.61 [-43.6, -47.7] 2018 - 458 60.61 [-43.99, 279] 2015 - 458 60.61 [-43.99, 279] 2015 - 458 60.61 [-43.99, 279] 2015 - 458 60.61 [-43.99, 279] 2015 - 458 60.61 [-43.99, 279] 2015 - 458 60.61 [-43.99, 279] 2015 - 458 60.61 [-43.99, 279] 2015 - 458 60.61 [-43.99, 279] 2015 - 458 60.61 [-43.99, 279] 2015 - 458 60.61 [-43.99, 279] 2015 - 458 60.61 [-43.99, 27		
Castle 2010 - LMA 1‡ 25.7 8.4 75 70.3 32.82 68 6.0% -44.60 [+52.63, -36.57] 2010 Castle 2010 - LMA 2§ 21.5 6.19 75 59.1 25.54 72 6.4% -37.60 [+43.66, -31.54] 2010 Ophir 2014 - LMA † 18.9 7.57 117 34.7 11.4 117 6.9% -15.80 [+18.28, -13.32] 2014 + Wang 2015 - LMA † 10.51 4.39 40 17.86 6.38 40 6.9% -7.35 [+9.75, -4.95] 2015 + ubtotal [95% CIIII] 478 458 60.6% -27.14 [-36.32, -17.96] Heterogeneity: Tau <sup>2</sup> = 201.99; Chi <sup>2</sup> = 399.34; df = 9 (P < 0.00001); l <sup>2</sup> = 98% summary effect test: 2 - 5.79 (P < 0.00001) 11) 11.2 2 <sup>m</sup> Generation Devices Ophir 2014 - LMA - 26** 18.6 4.13 117 34.7 11.4 117 6.9% -16.10 [+18.30, -13.90] 2014 - Plazikowski 2018 - LMA - 26** 9.64 2.34 30 24.36 7.01 30 6.8% -15.20 [-17.47, -12.93] 2014 - Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.67; df = 2 (P = 0.71); l <sup>2</sup> = 0% Summary effect test: 2 - 22.28 (P < 0.00001) 11.3 Subgrupo ILMA Greenland 2007 - ILMA* 14 3.5 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2007 - Weaver 2015 - LMA* 52 24.52 37 60.6 25.45 37 5.2% -8.60 [-19.99, 2.79] 2015 - Heterogeneity: Tau <sup>2</sup> = 13.27; Chi <sup>2</sup> = 7.82; df = 9 (P = 0.02); l <sup>2</sup> = 74%		
Castle 2010 - LMA 2§ 21.5 6.19 75 59.1 25.54 72 6.4% -37.60 [+3.66, -31.54] 2010 Ophir 2014 - LMA† 18.9 7.57 117 34.7 11.4 117 6.9% -15.80 [+18.28, -13.32] 2014 Wang 2015 - LMA† 10.51 4.39 40 17.86 6.38 40 6.9% -7.35 [+3.75, -4.95] 2015 478 458 60.6% -27.14 [-36.32, -17.96] Heterogeneity: Tau <sup>2</sup> = 201.99; Chi <sup>2</sup> = 399.34; df = 9 (P < 0.00001); l <sup>2</sup> = 98% Summary effect test: Z = 5.79 (P < 0.00001) 11) 11.2 $2^{co}$ Generation Devices Ophir 2014 - LT↑† 19.5 5.22 117 34.7 11.4 117 6.9% -16.10 [-18.30, -13.90] 2014 + Plazikowski 2018 - LMA - 2G** 9.64 2.34 30 24.36 7.01 30 6.8% -14.72 [-17.36, -12.08] 2018 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.67; df = 2 (P = 0.71); l <sup>2</sup> = 0% Summary effect test: Z = 22.28 (P < 0.00001) 11.3 Subgrupo ILMA Greenland 2007 - ILMA* 14 3.5 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2007 + Weaver 2015 - ILMA* 10 3.11 30 24.36 7.01 30 6.8% -14.36 [-17.0, -11.62] 2018 + Heterogeneity: Tau <sup>2</sup> = 13.27; Chi <sup>2</sup> = 7.82; df = 9 (P = 0.02); l <sup>2</sup> = 74%		
Dephir 2014 - LMA+ 18.9 7.57 117 34.7 11.4 117 6.9% -15.80 [-18.28, -13.32] 2014 Wang 2015 - LMA+ 10.51 4.39 40 17.86 6.38 40 6.9% -7.35 [-9.75, -4.95] 2015 wubtotal (95% (IIII)) 478 458 60.6% -27.14 [-36.32, -17.96] Heterogeneity: Tau <sup>2</sup> = 201.99; Chi <sup>2</sup> = 399.34; df = 9 (P < 0.00001); l <sup>2</sup> = 98% wummary effect test: Z = 5.79 (P < 0.00001) 01) 1.1.2 2 <sup>no</sup> Generation Devices Ophir 2014 - LMA - 26 <sup>**</sup> 18.6 4.13 117 34.7 11.4 117 6.9% -16.10 [-18.30, -13.90] 2014 + Plazikowski 2018 - LMA - 26 <sup>**</sup> 9.64 2.34 30 24.36 7.01 30 6.8% -14.72 [-17.36, -12.08] 2018 + Summary effect test: Z = 2.2.28 (P < 0.00001) 1.1.3 Subgrupo ILMA Greenland 2007 - ILMA <sup>*</sup> 14 3.5 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2007 + Weaver 2015 - ILMA <sup>*</sup> 10 3.11 30 24.36 7.01 30 6.8% -14.36 [-17.10, -11.62] 2018 + Heterogeneity: Tau <sup>2</sup> = 13.27; Chi <sup>2</sup> = 7.82; df = 9 (P = 0.02); l <sup>2</sup> = 74%		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		
478   458   60.6%   -27.14 [.36.32, -17.96]     Heterogeneity: Tau <sup>2</sup> = 201.99; Chi <sup>2</sup> = 399.34; df = 9 (P < 0.00001); l <sup>2</sup> = 98%		
Subtotal (95% CIII) Heterogeneity: Tau <sup>2</sup> = 201.99; Chi <sup>2</sup> = 399.34; df = 9 (P < 0.00001); l <sup>2</sup> = 98% Summary effect test: Z = 5.79 (P < 0.00001) 11) <b>1.1.2</b> 2 <sup>no</sup> Generation Devices Ophir 2014 - LMA - 26 <sup>**</sup> 18.6 4.13 117 34.7 11.4 117 6.9% -16.10 [-18.30, -13.90] 2014 - Plazikowski 2018 - LMA - 26 <sup>**</sup> 9.64 2.34 30 24.36 7.01 30 6.8% -14.72 [-17.36, -12.08] 2014 - Plazikowski 2018 - LMA - 26 <sup>**</sup> 9.64 2.34 30 24.36 7.01 30 6.8% -14.72 [-17.36, -12.08] 2018 - Subtotal (95% CIIII) 264 264 20.6% -15.42 [-16.77, -14.06] + Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.67; df = 2 (P = 0.71); l <sup>2</sup> = 0% Summary effect test: Z = 22.28 (P < 0.00001) <b>1.1.3 Subgrupo ILMA</b> Greenland 2007 - ILMA* 14 3.5 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2007 - Weaver 2015 - ILMA* 52 24.52 37 60.6 25.45 37 5.2% -8.60 [-19.99, 2.79] 2015 - Plazikowski 2018 - ILMA* 10 3.11 30 24.36 7.01 30 6.8% -10.99 [-16.08, -5.90] - Subtotal (95% CIIII) 55 20 24.52 7.26 50 2018 - Heterogeneity: Tau <sup>2</sup> = 13.27; Chi <sup>2</sup> = 7.82; df = 9 (P = 0.02); l <sup>2</sup> = 74%		
$\begin{array}{c} \text{Heterogeneity: } Tau^2 = 201.99; \ \text{Chi}^2 = 399.34; \ \text{df} = 9 \ (P < 0.00001); \ l^2 = 98\% \\ \text{Summary effect test: } Z = 5.79 \ (P < 0.00001) \ 11) \\ \textbf{1.1.2 } 2^{00} \ \text{ Generation Devices} \\ \hline \text{Ophir 2014 - LT} + & 18.6 \ 4.13 \ 117 \ 34.7 \ 11.4 \ 117 \ 6.9\% \ -16.10 \ [-18.30, -13.90] \ 2014 \\ \textbf{-} \\ \text{Ophir 2014 - LT} + & 19.5 \ 5.22 \ 117 \ 34.7 \ 11.4 \ 117 \ 6.9\% \ -15.20 \ [-17.47, -12.93] \ 2014 \\ \textbf{-} \\ \text{Ophir 2014 - LT} + & 19.5 \ 5.22 \ 117 \ 34.7 \ 11.4 \ 117 \ 6.9\% \ -15.20 \ [-17.47, -12.93] \ 2014 \\ \textbf{-} \\ \text{Plazikowski 2018 - LMA - 2G^{**} \ 9.64 \ 2.34 \ 30 \ 24.36 \ 7.01 \ 30 \ 6.8\% \ -14.72 \ [-17.36, -12.08] \ 2018 \\ \textbf{+} \\ \text{Subtotal (95\% CIIII)} & 264 \ 264 \ 264 \ 20.6\% \ -15.42 \ [-16.77, -14.06] \\ \textbf{+} \\ \text{Heterogeneity: } Tau^2 = 0.00; \ \text{Chi}^2 = 0.67; \ \text{df} = 2 \ (P = 0.71); \ l^2 = 0\% \\ \text{Summary effect test: } Z = 22.28 \ (P < 0.00001) \\ \textbf{1.1.3 Subgrupo ILMA & } \\ \text{Greenland 2007 - ILMA^* } 14 \ 3.5 \ 18 \ 22.2 \ 6.6 \ 18 \ 6.8\% \ -8.20 \ [-11.65, -4.75] \ 2007 \\ \textbf{-} \\ \text{Weaver 2015 - ILMA^* } 52 \ 24.52 \ 37 \ 60.6 \ 25.45 \ 37 \ 5.2\% \ -8.60 \ [-19.99, 2.79] \ 2015 \\ \textbf{-} \\ \text{Plazikowski 2018 - ILMA^* } 10 \ 3.11 \ 30 \ 24.36 \ 7.01 \ 30 \ 6.8\% \ -10.39 \ [-16.08, -5.90] \\ \textbf{-} \\ \text{Subtotal (95\% CIIII)} & \textbf{-} \\ \text{Heterogeneity: } Tau^2 = 13.27; \ \text{Chi}^2 = 7.82; \ \text{df} = 9 \ (P = 0.02); \ l^2 = 74\% \\ \end{array}$		
1.1.2 2 <sup>nn</sup> Generation Devices     Ophir 2014 - LMA - 2G**   18.6   4.13   117   34.7   11.4   117   6.9%   -16.10 [-18.30, -13.90]   2014   -     Ophir 2014 - LT††   19.5   5.22   117   34.7   11.4   117   6.9%   -15.20 [-17.47, -12.93]   2014   -     Plazikowski 2018 - LMA - 2G**   9.64   2.34   30   24.36   7.01   30   6.8%   -14.72 [-17.36, -12.08]   2018   -     Plazikowski 2018 - LMA - 2G**   9.64   2.34   30   24.36   7.01   30   6.8%   -14.72 [-17.36, -12.08]   2018   -     Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.67; df = 2 (P = 0.71); l <sup>2</sup> = 0%   Summary effect test: Z = 22.28 (P < 0.00001)		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		
Ophir 2014 - LT↑↑   19.5   5.22   117   34.7   11.4   117   6.9%   -15.20   [-17.47, -12.93]   2014   -     Plazikowski 2018 - LMA - 20**   9.64   2.34   30   24.36   7.01   30   6.8%   -14.72   [-17.36, -12.08]   2018   -     Subtotal (95% CIII)   264   264   264   264   264   264   20.6%   -15.42   [-16.77, -14.06]   +     Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.67; df = 2 (P = 0.71); l <sup>2</sup> = 0%   -   -   -   -   -   -     Summary effect test: Z = 22.28 (P < 0.00001)		
Opling 2014 - CFTT 19:3 5:22 117 34.7 11.4 117 59.8 19:20 11.4, 12.59 2014 Flazkowski 2018 - LMA - 2G** 9.64 2.34 30 24.36 7.01 30 6.8% -15.20 [17.47, 12.59] 2014 Flazkowski 2018 - LMA - 2G** 9.64 2.34 30 24.36 7.01 30 6.8% -15.42 [-16.77, -14.06] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.67; df = 2 (P = 0.71); l <sup>2</sup> = 0% Summary effect test: Z = 22.28 (P < 0.00001) 1.1.3 Subgrupo ILMA Greenland 2007 - ILMA* 14 3.5 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2007 Weaver 2015 - ILMA* 52 24.52 37 60.6 25.45 37 5.2% -8.60 [-19.99, 2.79] 2015 Plazkowski 2018 - ILMA* 10 3.11 30 24.36 7.01 30 6.8% -14.36 [-17.10, -11.62] 2018 Subtotal (95% CI <sup>III</sup> ) Heterogeneity: Tau <sup>2</sup> = 13.27; Chi <sup>2</sup> = 7.82; df = 9 (P = 0.02); l <sup>2</sup> = 74%		
Hazhovski 2018 - LiMA* 20 3.04 2.34 30 7.01 30 24.30 7.01 30 0.8% 14.72 [11.30, 12.06] 2018 Jubitotal (95% C111) 264 264 264 264 264 264 264 264 264 266 15.42 [16.77, -14.06] 14 14 14 14 15 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2007 Hazkovski 2015 - LLMA* 14 3.5 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2007 + 12.00 [-11.05] 2018 12 10 3.11 30 24.36 7.01 30 6.8% -14.36 [-17.10, -11.62] 2018 + 12.00 [-10.08, -5.90] 14 14 14 15 18 22.2 6.6 18 6.8% -14.36 [-17.10, -11.62] 2018 + 12.00 [-10.08, -5.90] 14 14 15 18 22.2 6.6 18 6.8% -14.36 [-17.10, -11.62] 2018 + 12.00 [-10.08, -5.90] 14 14 14 14 14 14 15 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2007 + 12.00 [-11.65, -4.75] 2007 + 12.00 [-11.65, -4.75] 2007 + 12.00 [-11.08, -5.90] 14 14 14 14 15 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2017 + 12.00 [-11.65, -4.75] 2017 + 12.00 [-11.08, -5.90] 14 14 14 14 14 15 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2007 + 12.00 [-11.65, -4.75] 2007 + 12.00 [-11.08, -5.90] 14 14 14 14 14 14 14 14 15 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2017 + 12.00 [-11.08, -5.90] 14 14 14 14 14 14 14 14 15 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2007 + 12.00 [-11.08, -5.90] 14 14 14 14 14 15 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2007 + 12.00 [-11.65, -4.75] 2018 + 12.00 [-11.08, -5.90] 14 14 14 14 14 14 14 14 14 14 14 14 14		
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.67; df = 2 (P = 0.71); l <sup>2</sup> = 0% Summary effect test: Z = 22.28 (P < 0.00001) <b>1.1.3 Subgrupo ILMA</b> 3reenland 2007 - ILMA* 14 3.5 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2007 ← Neaver 2015 - ILMA* 52 24.52 37 60.6 25.45 37 5.2% -8.60 [-19.99, 2.79] 2015 ← Plazikowski 2018 - ILMA* 10 3.11 30 24.36 7.01 30 6.8% -14.36 [-17.10, -11.62] 2018 ← Subtotal (95% Cl <sup>11</sup> ) Heterogeneity: Tau <sup>2</sup> = 13.27; Chi <sup>2</sup> = 7.82; df = 9 (P = 0.02); l <sup>2</sup> = 74%		
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.67; df = 2 (P = 0.71); l <sup>2</sup> = 0% Jummary effect test: Z = 22.28 (P < 0.00001) <b>1.1.3 Subgrupo ILMA</b> Jreenland 2007 - ILMA* 14 3.5 18 22.2 6.6 18 6.8% -8.20 [-11.65, -4.75] 2007 Weaver 2015 - ILMA* 52 24.52 37 60.6 25.45 37 5.2% -8.60 [-19.99, 2.79] 2015 Jazikowski 2018 - ILMA* 10 3.11 30 24.36 7.01 30 6.8% -14.36 [-17.10, -11.62] 2018 Subtotal (95% C( <sup>111</sup> ) Heterogeneity: Tau <sup>2</sup> = 13.27; Chi <sup>2</sup> = 7.82; df = 9 (P = 0.02); l <sup>2</sup> = 74%		
isummary effect test: Z = 22.28 (P < 0.00001)		
Greenland 2007 - ILMA*   14   3.5   18   22.2   6.6   18   6.8%   -8.20 [-11.65, -4.75]   2007     Veaver 2015 - ILMA*   52   24.52   37   60.6   25.45   37   5.2%   -8.60 [-19.99, 2.79]   2015     Plazikowski 2018 - ILMA*   10   3.11   30   24.36   7.01   30   6.8%   -10.99 [-16.08, -5.90]     Subtotal (95% CI <sup>III</sup> )   85   18.8%   -10.99 [-16.08, -5.90]   -10.99 [-16.08, -5.90]   -10.99 [-16.08, -5.90]		
3reenland 2007 - ILMA*   14   3.5   18   22.2   6.6   18   6.8%   -8.20 [-11.65, -4.75]   2007     Veaver 2015 - ILMA*   52   24.52   37   60.6   25.45   37   5.2%   -8.60 [-19.99, 2.79]   2015     Plazikowski 2018 - ILMA*   10   3.11   30   24.36   7.01   30   6.8%   -10.99 [-16.08, -5.90]     Subtotal (95% CI <sup>III</sup> )   85   18.8%   -10.99 [-16.08, -5.90]   -10.99 [-16.08, -5.90]   -10.99 [-16.08, -5.90]		
Neaver 2015 - ILMA*   52   24.52   37   60.6   25.45   37   5.2%   -8.60 [-19.99, 2.79]   2015     Plazikowski 2018 - ILMA*   10   3.11   30   24.36   7.01   30   6.8%   -14.36 [-17.10, -11.62]   2018     Subtotal (95% CI <sup>III</sup> )   85   85   18.8%   -10.99 [-16.08, -5.90]   +     Heterogeneity: Tau <sup>2</sup> = 13.27; Chi <sup>2</sup> = 7.82; df = 9 (P = 0.02); i <sup>2</sup> = 74%   -   -   -   +		
2lazikowski 2018 - ILMA*   10   3.11   30   24.36   7.01   30   6.8%   -14.36 [-17.10, -11.62]   2018     Subtotal (95% Cl <sup>III</sup> )   85   85   18.8%   -10.99 [-16.08, -5.90]   ◆     Heterogeneity: Tau <sup>2</sup> = 13.27; Chi <sup>2</sup> = 7.82; df = 9 (P = 0.02); i <sup>2</sup> = 74%		
85     85     18.8%     -10.99 [-16.08, -5.90]       Subtotal (95% CI <sup>III</sup> )     +       Heterogeneity: Tau <sup>2</sup> = 13.27; Chi <sup>2</sup> = 7.82; df = 9 (P = 0.02); l <sup>2</sup> = 74%		
ubtotal (95% C1 <sup>111</sup> ) Heterogeneity: Tau <sup>2</sup> = 13.27; Chi <sup>2</sup> = 7.82; df = 9 (P = 0.02); i <sup>2</sup> = 74%		
Summary effect test: $7 = 4.23$ (P < 0.00001) 1		
Subtotal (95% C[111]) 827 807 100.0% -21.77 [-26.94, -16.59]		
Summary effect test: 7 = 8.24 (0 < 0.00001) 21) -50 -25 0 25 5	50	
Suproju difference test: Chi'= 9.16; df = 2 (P = 0.01); l <sup>2</sup> = 78.2% Suproju difference test: Chi'= 9.16; df = 2 (P = 0.01); l <sup>2</sup> = 78.2%	oscopy	

\*ILMA = Laryngeal mask capable of guiding orotracheal intubation; <sup>†</sup>LMA = Laryngeal mask; <sup>‡</sup>LMA1 = Laryngeal mask 1<sup>st</sup> attempt; <sup>§</sup>LMA2 = Laryngeal mask 2<sup>nd</sup> attempt; <sup>I</sup>LMA (A) = Laryngeal mask (anesthesiologists); <sup>§</sup>LMA (O) = Laryngeal mask (other professionals not anesthetists); \*\*LMA-2G = 2<sup>nd</sup> generation laryngeal mask; <sup>††</sup>LT = Laryngeal tube; <sup>‡‡</sup>SD = Standard Deviation; <sup>§</sup>IV = Inverse of the variance; <sup>II</sup>CI = Confidence interval

Figure 4 - Mean time of the techniques of direct laryngoscopy and insertion of supraglottic devices

According to Figure 4, it is observed that the supraglottic insertion technique obtained a lower mean of time spent compared to the direct laryngoscopy technique with the orotracheal tube. The general and subgroup result was statistically significant and favorable to the supraglottic device. Regarding the evaluation of the success rate in the first attempt of each applied technique, and when considering the use of level C personal protective equipment by the health professionals, eight studies were collected for meta-analysis. Moderate heterogeneity of significant effect and statistically significant summary effect were identified. The result was favorable for the supraglottic device, as shown in Figure 5.



\*ILMA = Laryngeal mask capable of guiding orotracheal intubation; <sup>†</sup>LMA = Laryngeal mask; <sup>‡</sup>LMA1 = Laryngeal mask 1<sup>st</sup> attempt; <sup>§</sup>LMA (A) = Laryngeal mask (anesthesiologists); <sup>I</sup>LMA (O) = Laryngeal mask (another non-anesthesiologist); <sup>I</sup>LMA-2G = 2<sup>nd</sup> generation laryngeal mask; \*\*LT = Laryngeal tube; <sup>††</sup>MH = Mantel-Haenszel; <sup>‡‡</sup>CI = Confidence interval

Figure 5 - Success rate in the first attempt at orotracheal intubation and insertion of supraglottic device

#### Discussion

For the "reduction of time spent on each procedure" outcome, the systematic review shows that the mean time to insert supraglottic devices is shorter compared to the orotracheal tube. Subgroup analysis was useful, as it reasserted favoring supraglottic devices through statistically significant results.

Concerning the second outcome, "success in the first attempt", the result showed moderate heterogeneity with significant effect (p = 0.02) and a statistically significant summary effect in the difference of proportion: 0.06 [95% CI: 0.03; 0.10]; (p = 0.0008);  $I^2 = 52\%$ . In the analysis of the success rate in the first attempt of each applied technique, this systematic review obtained 89.56% for direct laryngoscopy and 97.12% for the insertion of a supraglottic device. The results of the systematic review were reinforced by other similar results, with 85% success rate for direct laryngoscopy<sup>(29)</sup>, and 100% for the supraglottic device<sup>(30)</sup>.

The evaluation of the level of evidence presented in the studies by the GRADE system, with regard to the "reduction of time for performing direct laryngoscopy compared to the insertion of a supraglottic device" outcome, found a moderate level of evidence. Regarding the "success in the first attempt of each technique" outcome, a moderate level of evidence was also obtained. Demonstrated by the GRADE system, a strong recommendation force that favors 2<sup>nd</sup> generation supraglottic devices and the laryngeal masks capable of guiding orotracheal intubation, and a weak recommendation strength was identified in relation to the 1<sup>st</sup> generation supraglottic devices.

In accident scenarios with multiple victims, with or without involvement of a chemical, biological or radiological agent, one of the objectives is to provide a prior airway for as many people as possible<sup>(24,30)</sup>. Therefore, the use of supraglottic devices by the health professionals with personal protective equipment in these scenarios has been systematically studied. In general, the results point to ease of use and rapid insertion<sup>(30-32)</sup>. In addition, less stringent training requirements for its use have been confirmed when compared to orotracheal intubation<sup>(30-31)</sup>.

Another aspect highlighted is related to the clinical conditions of seriously infected victims, who require advanced immediate life support, which includes the use of ventilatory support techniques, a priority to reduce mortality<sup>(33)</sup>. Even in these cases, orotracheal intubation is the gold standard to ensure the airway and prevent death<sup>(34)</sup>.

In the case of the evolution of 2<sup>nd</sup> generation supraglottic devices, feasible improvements have made them more useful and applicable in different environments, like the pre-hospital, in-hospital emergency, and surgical environments<sup>(24)</sup>. There are currently a variety of 2<sup>nd</sup> generation supraglottic devices, which have similar characteristics, such as anti-bite system, route for gastric emptying, better airway sealing, and structure to be a ventilatory support route under high pressures. Such characteristics make supraglottic devices a technology that has been gaining space and importance in the daily care of the health professionals<sup>(13,24,32)</sup>. It can be inferred that the effectiveness and the performance among the 2<sup>nd</sup> generation supraglottic devices of this systematic review reflected in the homogeneity of this subgroup.

In addition, emergency orotracheal intubation outside the operating room is associated with significant operational challenges, which include a higher incidence of difficult intubation due to environmental factors, possible lack of experience in laryngoscopy, rapid deterioration of clinical conditions, and risk of regurgitation<sup>(13)</sup>.

Paradoxically, despite all the selected studies, a study was retrieved, whose participants were emergency physicians with level C personal protective equipment, performing orotracheal intubation and the insertion of supraglottic devices in cadavers<sup>(15)</sup>. The results suggest orotracheal intubation as a faster technique, with statistically significant data (p = 0.02) and with a higher success rate in the first attempt (direct laryngoscopy = 58% and supraglottic device = 21%)<sup>(15)</sup>. However, it is noteworthy that this study was eliminated from this systematic review because it did not present data with the respective standard deviation or means for calculating it, which made insertion in the meta-analysis unfeasible, in compliance with the provisions of the inclusion criteria. Thus, a high risk of attrition bias was identified due to the fact that it did not present the standard deviation in the study. It is worth mentioning that few participants in this study had previous experience with a supraglottic device, which meant that the researchers promoted a preliminary training, in which each participant performed the two procedures three times. These same participants had an Advanced Life Support Course, and reported having performed direct laryngoscopy at least 30 times in their career. In view of the above, after assessing the risk of bias by the highest degree identified in the domains, the general assessment of this study<sup>(15)</sup> was considered high risk, weakening the reliability of its results. This was the only study that was contrary to the favorable trend towards supraglottic devices.

Regarding the potential limitations of this study, it is emphasized that the systematic review evaluated different types of supraglottic devices, as well as it considered different methodologies, professional categories or areas of activity, which reflected in heterogeneity. However, the summary effect was strongly favorable to supraglottic devices, in all the meta-analyses.

Another limitation concerns the instruments on which the ventilatory support techniques were applied. As explained in Figure 2 on the characterization of the eligible studies, mannequins and adult humans were used. The

www.eerp.usp.br/rlae

selection brought together nine studies with mannequins, and one study with 60 human beings submitted to surgical and orthopedic interventions. The decision to jointly analyze both studies on mannequins and human beings maintained an adequate comparative uniformity, as both were immobile and without reaction during the interventions. In addition, the patients were relatively healthy; sedated and relaxed; monitored and with venous access; in optimal hemodynamic and ventilatory conditions; no reactions during the insertion of devices<sup>(24)</sup>. The inclusion of this study with humans in the metaanalyses reinforced the trend of studies on mannequins. However, it must be admitted that if all the studies involved human beings, which was not found, the impact and applicability of the recommendations generated by this systematic review would be greater. In addition, the study participants treated one patient or one mannequin at a time; did not see oral cavity with secretions; nor were there conditions for multiple injuries, seizures or hypoxia. Such description does not correspond to a real intervention on a victim in frank respiratory insufficiency by a chemical, biological or radiological agent, in the historical context of an accident with multiple victims, in which the objective is to provide a safe airway for the largest number of victims possible with chances to survive. Finally, the time until the airway is installed is a crucial factor for survival and stabilization of the victim who is physically compromised, unconscious, dyspnoic, with increased secretions in the airways and hypoxemic<sup>(10,35)</sup>.

Therefore, it should be considered that nine of the ten studies in this systematic review were carried out in a skills laboratory, that is, in a closed environment, with ideal brightness, controlled temperature and mannequins, which may not reflect reality<sup>(10,14,35)</sup>. In addition to the above, scholars in the field comment on the difficulty of developing research studies of this nature with human beings, in relation to the use of chemical warfare agents<sup>(14)</sup>.

### Conclusion

The systematic review points to supraglottic devices as being faster to the detriment of orotracheal intubation, under the "reduction in the time to perform ventilatory support techniques" outcome. Thus, with a moderate level of evidence, supraglottic devices are recommended as the first choice in an emergency and disaster scenario involving chemical, biological or radiological agents, which may involve the need to care for multiple contaminated victims, where road management aerial is required. Subsequently, once the patient is stabilized, the environment is better known and has a greater supply of professionals and material, the supraglottic device can be exchanged for the orotracheal tube. Regarding the "success in the first attempt" outcome there is a moderate level of evidence that the supraglottic device has a higher percentage of correct responses compared to the orotracheal tube.

These outcomes are important because they directly impact the survival of a victim in respiratory failure and provide substantial subsidies in the decision-making process of the health professionals, nurse included, on which technology should be used as a priority because it is faster and more likely to be successful on the first attempt.

The GRADE system found a strong recommendation force, which favored the indication of 2nd generation supraglottic devices and of the laryngeal masks capable of guiding orotracheal intubation; and a weak recommendation strength was identified favoring 1st generation supraglottic devices.

Despite the advances and recommendations that this systematic review has provided, it is still necessary to develop clinical studies with better methodological robustness, in order to obtain recommendations with a higher level of evidence, especially due to the need for safety and quality of care.

### Acknowledgments

To Lisandra Rodrigues Risi for her collaboration as an independent reviewer.

### References

1. Price R. Syria and the Chemical Weapons Taboo. J Glob Secur Stud. 2019;4(1):37-52. doi: https://doi. org/10.1093/jogss/ogy040

2. Schmidt Pasqualoto A, Martins de Albuquerque I, Bastos Pereira M, Naimaier Bertolazi A, Pessota Ribeiro da Silva CS, Cervi Prado AL, et al. Epidemiological profile, respiratory signs and symptoms of individuals who inhaled toxic smoke in Kiss nightclub fire, Santa Maria, RS, Brazil. ConScientiae Saude. 2015;14(2) :229-35. doi: https:// doi.org/10.5585/conssaude.v14n2.5377

3. Franklin SM. A Comparison of Personal Protective Standards: Caring for Patients With Ebola Virus. Clin Nurs Spec. 2016;30(2):E1-8. doi: 10.1097/ NUR.00000000000183

4. Ventura D, Holzhacker V.Global Health and Human Rights: The First Ebola Case in Brazil. Lua Nova. 2016;98:107-40. doi: http://dx.doi.org/10.1590/0102-6445107-140/98

5. Wichmann D, Kreuels B, Schmiedel S, Kluge S. [Intensive care treatment of a patient with Ebola virus disease in Germany]. Med Klin Intensivmed Notfmed. 2017;112(1):38-41. doi: 10.1007/s00063-016-0140-5

6. Pacheco DAMRA, Rodrigues AAG, Silva CML. Ebola virus from neglected threat to global emergency state. Rev

Assoc Med Bras (1992). 2016(5);62:458-67. doi: http:// dx.doi.org/10.1590/1806-9282.62.05.458

7. Jansen LC, Razuck FB. Knowledge management in radiation protection: The Goiânia accident-Learning in the face of tragedy. Braz J Radiat Sci. 2018;6(2B). doi: https://doi.org/10.15392/bjrs.v6i2B.537

8. Udayasiri R, Knott J, McD Taylor D, Papson J, Leow F, Hassan FA. Emergency department staff can effectively resuscitate in level C personal protective equipment. Emerg Med Australas. 2007;19(2):113-21. doi: https:// doi.org/10.1111/j.1742-6723.2007.00918.x

9. Tokuda Y, Kikuchi M, Takahashi O, Stein GH. Prehospital management of sarin nerve gas terrorism in urban settings: 10 years of progress after the Tokyo subway sarin attack. Resuscitation. 2006;68(2):193-202. doi: https://doi. org/10.1016/j.resuscitation.2005.05.023

10. Garner A, Laurence H, Lee A. Practicality of performing medical procedures in chemical protective ensembles. Emerg Med Australas. 2004;16(2):108-13. doi: https://doi.org/10.1111/j.1742-6723.2004.00560.x

11. Mitchell CJ, Kernohan WG, Higginson R. Are emergency care nurses prepared for chemical, biological, radiological, nuclear or explosive incidents? Int Emerg Nurs. 2012;20(3):151-61. doi: 10.1016/j.ienj.2011.10.001

12. Wiyor HD, Coburn JC, Siegel KL. Impact of Clinician Personal Protective Equipment on Medical Device Use During Public Health Emergency: A Review. Disaster Med Public Health Prep. 2019:1-11. doi: https://doi. org/10.1017/dmp.2019.52

 Gordon J, Cooper RM, Parotto M. Supraglottic airway devices: indications, contraindications and management.
Minerva Anestesiol. 2018;84(3):389-97. doi: 10.23736/ S0375-9393.17.12112-7

14. Rodgers GC Jr, Condurache CT. Antidotes and treatments for chemical warfare/terrorism agents: an evidence-based review. Clin Pharmacol Ther. 2010;88(3):318-27. doi: 10.1038/clpt.2010.152

15. Scott Taylor R, Pitzer M, Goldman G, Czysz A, Simunich T, Ashurst J. Comparison of intubation devices in level C personal protective equipment: a cadaveric study. Am J Emerg Med. 2018;36(6):922-5. doi: https://doi. org/10.1016/j.ajem.2017.10.047

16. Plazikowski E, Greif R, Marschall J, Pedersen TH, Kleine-Brueggeney M, Albrecht R, et al. Emergency Airway Management in a Simulation of Highly Contagious Isolated Patients: both Isolation Strategy and Device Type Matter. Infect Control Hosp Epidemiol. 2018;39(2):145-51. doi: https://doi.org/10.1017/ice.2017.287

McHugh ML. Interrater reliability: the kappa statistic.
Biochemia Medica: 2012;22(3):276-82.

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher
Oxman AD, et al. The Cochrane Collaboration's tool

for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: https://doi.org/10.1136/bmj.d5928 19. Borenstein M, Higgins JPT, Hedges LV, Rothstein HR. Basics of meta-analysis: I2 is not an absolute measure of heterogeneity. Res Synth Methods. 2017;8(1):5-18. doi: https://doi.org/10.1002/jrsm.1230

 Brożek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64(5):669-77. doi: https://doi.org/10.1111/j.1398-9995.2009.01973.x
Ben-Abraham R, Weinbroum AA. Laryngeal mask airway control versus endotracheal intubation by medical personnel wearing protective gear. Am J Emerg Med. 2004;22(1):24-6. doi: https://doi.org/10.1016/j.ajem.2003.09.006

22. Castle N, Owen R, Hann M, Clark S, Reeves D, Gurney I. Impact of Chemical, Biological, Radiation, and Nuclear Personal Protective Equipment on the performance of low- and high-dexterity airway and vascular access skills. Resuscitation. 2009;80(11):1290-5. doi: https://doi. org/10.1016/j.resuscitation.2009.08.001

23. Castle N, Owen R, Clarke S, Hann M, Reeves D, Gurney I. Does position of the patient adversely affect successful intubation whilst wearing CBRN-PPE? Resuscitation. 2010;81(9):1166-71. doi: https://doi.org/10.1016/j. resuscitation.2010.05.009

24. Flaishon R, Sotman A, Ben-Abraham R, Rudick V, Varssano D, Weinbroum AA. Antichemical protective gear prolongs time to successful airway management: a randomized, crossover study in humans. Anesthesiology. 2004;100(2):260-6. doi: 10.1097/00000542-200402000-00013

25. Greenland KB, Tsui D, Goodyear P, Irwin MG. Personal protection equipment for biological hazards: does it affect tracheal intubation performance? Resuscitation. 2007;74(1):119-26. doi: https://doi.org/10.1016/j. resuscitation.2006.11.011

26. Ophir N, Ramaty E, Rajuan-Galor I, Rosman Y, Lavon O, Shrot S, et al. Airway control in case of a mass toxicological event: superiority of second-generation supraglottic airway devices. Am J Emerg Med. 2014;32(12):1445-9. doi: https://doi.org/10.1016/j.ajem.2014.08.067

27. Wang CC, Chaou CH, Tseng CY, Lin CC. The effect of personal protective equipment on emergency airway management by emergency physicians: a mannequin study. European J Emerg Med. 2016;23(2):124-9. doi: https://doi.org/10.1097/MEJ.00000000000157

Corresponding author: Israel Baptista de Souza Borges E-mail: israelbsborges@gmail.com b https://orcid.org/0000-0002-7083-3580

www.eerp.usp.br/rlae

28. Weaver KR, Barr GC, Long KR, Diaz L, Ratner AS, Reboul JP, et al. Comparison of airway intubation devices when using a biohazard suit: a feasibility study. Am J Emerg Med. 2015;33(6):810-4. doi: https://doi.org/10.1016/j. ajem.2015.02.051

29. Kim TH, Kim CH, Shin SD, Haam S. Influence of personal protective equipment on the performance of life-saving interventions by emergency medical service personnel. Simulation. 2016;92(10):893-8. doi: https://doi.org/10.1177/0037549716662322

30. Castle N, Pillay Y, Spencer N. Insertion of six different supraglottic airway devices whilst wearing chemical, biological, radiation, nuclear-personal protective equipment: a manikin study. Anaesthesia. 2011;66(11):983-8. doi: https://doi.org/10.1111/j.1365-2044.2011.06816.x

31. Goldik Z, Bornstein J, Eden A, Ben-Abraham R. Airway management by physicians wearing anti-chemical warfare gear: comparison between laryngeal mask airway and endotracheal intubation. Eur J Anaesthesiol. 2002;19(3):166-9. doi: https://doi.org/10.1017/S0265021502000297

32. Ben-Abraham R, Flaishon R, Sotman A, Ezri T, Weissenberg M, Weinbroum AA. Cuffed oropharyngeal airway (COPA) placement is delayed by wearing antichemical protective gear. Emerg Med J. 2008;25(12):847-50. doi: http://dx.doi.org/10.1136/emj.2008.059683

33. Claret PG, Bobbia X, Asencio R, Sanche E, Gervais E, Roger C, et al. Comparison of the Airtraq laryngoscope versus the conventional Macintosh laryngoscope while wearing CBRN-PPE. Eur J Emerg Med. 2016;23(2):119-23. doi: 10.1097/MEJ.00000000000220

34. Schröder H, Zoremba N, Rossaint R, Deusser K, Stoppe C, Coburn M, et al. Intubation performance using different laryngoscopes while wearing chemical protective equipment: a manikin study. BMJ Open. 2016;6(3):e010250. doi: http://dx.doi.org/10.1136/ bmjopen-2015-010250

35. Schumacher J, Arlidge J, Garnham F, Ahmad I. A randomised crossover simulation study comparing the impact of chemical, biological, radiological or nuclear substance personal protection equipment on the performance of advanced life support interventions. Anaesthesia. 2017; 72(5):592-7. doi: https://doi. org/10.1111/anae.13842

Received: Nov 26<sup>th</sup> 2019 Accepted: Apr 30<sup>th</sup> 2020

Associate Editor: Maria Lúcia Zanetti

Copyright © 2020 Revista Latino-Americana de Enfermagem This is an Open Access article distributed under the terms of the Creative Commons (CC BY).

This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials.